These assets include instruments that are key to the Roche NimbleGen microarray workflow, such as the 4-and-12-bay NimbleGen Hybridization Systems.
Roche said that it will transfer the manufacturing capabilities associated with these products to its own in-house facility.
"Acquiring these assets will allow Roche complete control over the production, support, and service of these products to ensure continued timely distribution, full support, and the high level of service our customers have grown to expect from Roche," Roche NimbleGen VP of Marketing Andreas Görtz said in a statement.
NimbleGen originally partnered with BioMicro for custom hybridization for its chips in 2007, before it was acquired by Roche later that year.
Financial terms of the agreement were not released.